cyclase-c

Plecanatide acetate is an analogue of Uroguanylin. It is an orally active guanylate cyclase-C (GC-C) receptor agonist.

Linaclotide, developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation, is a potent and selective guanylate cyclase C agonist.

Linaclotide acetate is used as an oral guanylate cyclase C agonist linaclotide; 14 amino acid peptide for the potential treatment of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation.

Plecanatide acetate is a agonist of guanylate cyclase-C (GC-C) receptor( EC50 of 190 nM in T84 cells), and shows anti-inflammatory activity in models of murine colitis.

MM 419447 is a guanylate cyclase-C agonist, and it is a metabolite of linaclotide. This compound, MM 419447, shows promise in the field of irritable bowel syndrome with constipation (IBS-C) research.

Dolcanatide, an orally active guanylate cyclase-C (GC-C) agonist, exhibits laxative, anti-nociceptive, and anti-inflammatory properties. It is utilized in research concerning inflammatory bowel disease [1] [2].

Cenderitide, a natriuretic peptide (NP) that combines C-type natriuretic peptide (CNP) with the C-terminus of Dendroaspis natriuretic peptide (DNP), serves as a potent agonist of the particulate guanylyl cyclase receptor (pGC). By activating both pGC-A and pGC-B receptors, it stimulates the production of the second messenger cGMP, suppresses aldosterone, and maintains glomerular filtration rate (GFR) without affecting blood pressure. This compound is particularly significant in the context of heart failure research, as evidenced by references [1] [2] [3].

[Tyr22] Calcitonin Gene Related Peptide (22-37), rat, refers to a fragment (amino acids 22-37) of the rat calcitonin gene-related peptide (CGRP) that targets the CGRP receptor and adenylate cyclase. While calcitonin is primarily produced by thyroid C cells, CGRP is predominantly secreted and stored within the nervous system [1].

Uroguanylin (human) serves as a natural ligand for the Guanylyl Cyclase C (GCC) receptor in metastatic colorectal cancer tumors and exhibits anti-tumor effects in an animal model of human colon cancer [1] [2].

Indusatumab vedotin (MLN-0264; AKT-264) is an antibody-drug conjugate (ADC) that combines a human anti-guanylate cyclase C (GCC) antibody with the microtubule-disruptor monomethyl auristatin E, demonstrating anti-proliferative effects on pancreatic cancer cell lines by arresting the cell cycle at the G2/M phase and inducing apoptosis [1].

PACAP (1-38), human, ovine, rat TFA is an endogenous neuropeptide and a high-affinity agonist for the PAC1 receptor. This 38-amino acid peptide binds to the PAC1 receptor to activate adenylate cyclase, inducing an increase in intracellular cAMP levels and triggering downstream signaling. Research demonstrates that C-terminal amidation of PACAP (1-38), human, ovine, rat TFA is dispensable for its biological activity at the PAC1 receptor, with the non-amidated form retaining full agonistic potency. It plays crucial roles in neuroprotection, regulation of insulin secretion, and vasodilation.

C-Type Natriuretic Peptide (1-53), from porcine, rat, and mouse sources, serves as an activator of particulate guanylate cyclase B (pGC-B), prominently found in endothelial cells, kidneys, and the heart. This peptide efficiently mediates a potent anti-fibrotic effect in human cardiac and renal fibroblasts through the production of the second messenger cGMP.

Uroguanylin (human) (TFA) is the natural ligand for the guanylate cyclase C (GCC) receptor expressed in metastatic colorectal cancer tumors. In animal models of human colon cancer, Uroguanylin (human) (TFA) demonstrates antitumor activity.